Second, the conventional treatment, being a supplementary treatment, does not have influence on other players involved in XLH pathogenesis such as high levels of FGF23 (Carpenter et al., 2010; Zhukouskaya et al., 2020) or accumulation in the extracellular matrix of other proteins or peptides (osteopontin, ASARM peptides, etc.)(Salmon et al., 2013, 2014; Coyac et al., 2018). The gene discussed is FGF23; the disease is X-linked hypophosphatemia.